Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM

Nizar Bahlis • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Daratumumab Dexamethasone Lenalidomide
MAIA

Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, gives an update on the MAIA trial (NCT02252172), which compared the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM) who are not candidates for high dose chemotherapy and autologous stem cell transplant. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Nizar Bahlis

Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023
Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea et al. • 15 Apr 2023
Updates in multiple myeloma
Nizar Bahlis et al. • 14 Apr 2023
2:09
First analysis of VenDd +/- V for RRMM shows unprecedented reponse
Nizar Bahlis • 10 Dec 2019

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals